We are pleased to share that Ms. Jennifer Che, our President and Managing Director, has once again been recognized in the IAM Strategy 300: The World’s Leading IP Strategists. This repeated honor reflects Jennifer’s outstanding strategic insight, deep expertise in intellectual property, and continued leadership in helping clients develop and implement IP strategies that create long-term value.  


The IAM Strategy 300 is a guide to the pioneers in the industry. It recognizes individuals who are “leading the way in developing and implementing strategies that maximize the value of IP portfolios.” Individuals are nominated by the community, and only those identified by market sources for their “exceptional skill sets and profound insights into patent matters” are featured in the IAM Strategy 300. Jennifer's consecutive inclusion on this list demonstrates her exceptional IP expertise, strategic insight, and dedicated commitment to driving long-term value for clients.


With a robust 20-year career as a scientist, patent attorney, and executive, Jennifer has helped numerous companies, institutions, inventors, and start-ups devise effective global intellectual property (IP) strategies. She excels at crafting integrated IP solutions that involve technical, regulatory, and long-range business needs. Jennifer's extensive experience in the U.S. and Greater China gives her a distinctive strategic eye for navigating complex cross-border IP challenges.


Please join us in congratulating Jennifer on this distinguished honor.

Best regards,

Eagle IP

Our Past Events

Recommended Insights

No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements

23 November 2018
Since 2010, the Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that discusses […]

China Hands Down First Batch of Patent Linkage “Paragraph IV” Litigation Results

30 June 2022
China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage. Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]

Diagnostic Claims in China

9 January 2020
The Chinese Patent Law excludes patenting methods of diagnosing or treating a disease. More specifically, this refers to processes of identifying, determining, or eliminating the cause or focus of diseases which are practiced directly on living human or animal bodies. Please keep in mind that instruments used for implementing these methods are still patentable. So […]

Breaking: China Released Drug Trial Data Protection Implementation Measures

22 May 2026
On May 15, 2026, China’s National Medical Products Administration (NMPA) officially announced the final Measures for the Implementation of Drug Trial Data Protection (“Measures”), effective May 15, 2026. These Measures provide important details supporting the recently announced Implementing Regulations of the Drug Administration Law (“Regulations” – also effective May 15, 2026), which formally introduced a […]
Top crossarrow-right